

Essential Information Document

**Discover Campaign:** Seeking Novel Immune-Inflammatory Targets, Pathways, and Therapies

**Commissioning company:** Almirall, S.A.

Contents:

1. **Application process and timeline overview**
2. **Success criteria**
3. **Eligibility criteria**
4. **Essential information on IP**
5. **Publication and presentation of results**
6. **Application process and timeline overview**

Submission

* Academic teams must complete and submit the application form associated with Almirall’s campaign by September 27th.
* All submissions should be provided to IN-PART using your university’s online dashboard or by emailing: [discover@in-part.co.uk](mailto:discover@in-part.co.uk)
* IN-PART will acknowledge receipt of your submission once received.

Review

* IN-PART will provide Almirall with all applications. The Almirall team will review all applications by the end of November

Decision outcome

Successful applicants

* Successful applicants, alongside a representative from their university’s Technology Transfer or Research Commercialisation team, will be informed by IN-PART, and introduced to the team at Almirall for next stage discussions

Unsuccessful applicants

* Feedback on unsuccessful applications will be provided by IN-PART shortly after 1st November.

1. **Success criteria**

Almirall S.A. will judge each submission against the following criteria:

* Alignment with RFP requirements (10%)
* Novelty and originality of approach: is the proposal more than a “me-too” offering, does it differentiate from other research being undertaken in the area? (30%)
* Feasibility of research (15%)
* Research team capability: what is the relevance of the background of researchers involved? (25%)
* Effectiveness of the approach: is there preliminary data or evidence to suggest the approach will be successful in a future clinical setting? (20%)

1. **Eligibility criteria**

* Applications must relate to research in chronic immune-inflammatory diseases
* Applicants must be working within the field of chronic immune-inflammatory diseases
* Please review the Discover campaign in detail to ensure your application fulfils the criteria for a successful application.

1. **Essential information on IP**

Prior to the commencement of the project, the institution will enter a project collaboration agreement with Almirall S.A.; the project collaboration agreement will set the provisions on IP, exploitation of the results and publication.

Briefly, under the project collaboration agreement:

* The institution will retain the ownership of any intellectual property it may bring or develop under the collaborative project
* The institution will grant Almirall S.A. a non-exclusive license to use the results of the research for internal research and development purposes only; this will not include, however, any tool compounds or lead compounds generated under the project
* Almirall will also ask for a first negotiation right to negotiate a future collaboration/business agreement, including a potential commercial license.

1. **Publication and presentation of results**

Publication or presentation of results will be generally encouraged, however, if this contains patentable subject matter or would materially jeopardise any intellectual property rights, the publication or presentation will be delayed until steps are taken for the protection of such subject matter.